Verve Therapeutics, Inc. (VERV)

Jul 25, 2025 - VERV was delisted (reason: acquired by LLY)

11.13

0.00 (0.00%)

Inactive · Last trade price on Jul 24, 2025

Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-181.01	-198.71	-200.07	-157.39	-120.31	-45.7
Depreciation & Amortization	6.84	6.75	5.46	2.8	1.54	1.33
Loss (Gain) From Sale of Investments	-10.33	-12.41	-14.38	-1.03	1.51	0.38
Stock-Based Compensation	44.09	43.26	35.12	22.48	7.07	0.85
Other Operating Activities	5.63	5.68	6.63	2.42	35.23	5.24
Change in Accounts Receivable	4.33	2.64	-5.89	-1.01	-	-
Change in Accounts Payable	2.21	-1.83	3.91	-5.22	6.83	-1.9
Change in Unearned Revenue	-4.63	5.31	28.54	20.01	-	-
Change in Other Net Operating Assets	-9.57	-8.38	-8.86	-5.41	-9.74	4.54
Operating Cash Flow	-142.46	-157.69	-149.55	-122.33	-77.88	-35.27
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Capital Expenditures	-4.53	-3.74	-9.28	-13.23	-4.36	-3.42
Investment in Securities	72.87	78.61	36.97	-142.72	-234.74	-47.7
Investing Cash Flow	68.34	74.88	27.69	-155.96	-239.1	-51.13

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Issuance of Common Stock	26.48	49.26	213.04	329.74	286.96	0.01
Other Financing Activities	-0.02	-0.07	-0.46	-0.78	-3.63	-
Financing Cash Flow	26.47	49.2	212.58	328.96	377.09	92.63

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Cash Flow	-47.65	-33.62	90.72	50.67	60.11	6.24

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Free Cash Flow	-146.98	-161.43	-158.83	-135.56	-82.24	-38.69
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-246.56%	-499.28%	-1350.84%	-6984.23%	-	-
Free Cash Flow Per Share	-1.71	-1.91	-2.48	-2.51	-3.06	-17.19
Levered Free Cash Flow	-64.11	-95.46	-110.19	-90.05	-42.25	-24.46
Unlevered Free Cash Flow	-64.11	-95.46	-110.19	-90.05	-42.25	-24.46

SEC Filings: 10-K · 10-Q